RxDoctor Payments Data

Steve Vaughan

Nurse Practitioner · Albuquerque, NMNPI 1982193413

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $2,932 of the $3,766 with a category attached, or 77.9%. 14 manufacturers reported payments, led by W. L. Gore & Associates, Inc. at 35.1% of the total. Reporting peaked in 2023 at $1,313 and has fallen 58.2% since, to $549 in 2025. Among nurse practitioner clinicians in NM with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$3,766in general payments, 2019–2025

Across 77 payments — averaging $48.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • W. L. Gore & Associates, Inc.$1K
  • Endologix LLC$834
  • Boston Scientific$553
  • Lemaitre Vascular, Inc.$245
  • Bard Peripheral Vascular, Inc.$152
  • Johnson & Johnson$133
  • plus $527 from 8 others

What the payments were for

  • Travel & lodging$65717%
  • Food & beverage$2,93278%
  • Education$1765%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,766 in reported general payments places this provider in the 95th percentile of 624 nurse practitioner providers in New Mexico.

See all nurse practitioner providers in New Mexico

Medicare billing

Part B allowed, 2024
$16,516
Medicare patients
128
Services billed
177

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban51$46,738
ClopidogrelClopidogrel Bisulfate178$3,237
Atorvastatin Calcium60$916
Cilostazol21$691
Rosuvastatin Calcium13$245

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$133$46,73851 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 624 nurse practitioner providers in New Mexico.

Other nurse practitioner in Albuquerque

See the full list for New Mexico

Where these figures come from

Is this you, or does something look wrong? →